Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
somatostatin receptor-targeted PET tracer
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
A somatostatin receptor-targeted PET tracer is a class of diagnostic radiopharmaceuticals used in positron emission tomography (PET) imaging to detect and localize tumors that overexpress somatostatin receptors (SSTRs), particularly neuroendocrine tumors (NETs) and meningiomas. These tracers typically consist of a somatostatin analog (such as octreotate or octreotide) conjugated to a chelator (like DOTA) and labeled with a positron-emitting radionuclide, most commonly gallium-68 (68Ga) or copper-64 (64Cu). Examples include 68Ga-DOTATATE, 68Ga-DOTATOC, and 64Cu-DOTATATE. By binding with high affinity to SSTRs (primarily SSTR2), these tracers allow for high-resolution imaging of SSTR-positive lesions, aiding in tumor staging, restaging, and selection of patients for somatostatin receptor-targeted therapies (such as peptide receptor radionuclide therapy, or PRRT).
- Other names
- somatostatin receptor-targeted PET imaging agentSSTR PET tracerSSTR-targeted PET tracer
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on somatostatin receptor-targeted PET tracer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on somatostatin receptor-targeted PET tracer.